Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Obesity

Free Subscription Articles published in Lancet Retrieve available abstracts of 34 articles: HTML format

Single Articles

July 2022
1. ABU DAYYEH BK, Bazerbachi F, Vargas EJ, Sharaiha RZ, et al
   Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial.
   Lancet. 2022 Jul 28. pii: S0140-6736(22)01280.
   PubMed     Abstract available
   
   
   June 2022
2. GOLUBIC R, Barber TM, Caleyachetty R
   Obesity definition for personalised treatment of type 2 diabetes.
   Lancet. 2022;399:2189.
   PubMed    
   
   
   
3. LINGVAY I, Sumithran P, Cohen RV, Roux CWL, et al
   Obesity definition for personalised treatment of type 2 diabetes Authors' reply.
   Lancet. 2022;399:2189-2190.
   PubMed    
   
   
   
4. SHI Q, Wang Y, Li S
   Pharmacotherapy for adults with overweight and obesity - Authors' reply.
   Lancet. 2022;399:2101.
   PubMed    
   
   
   
5. DAYYEH BKA
   Adjustable intragastric balloon for obesity - Author's reply.
   Lancet. 2022;399:2100.
   PubMed    
   
   
   
6. STURGISS E, Ball L, Blane D, Hennessy M, et al
   Pharmacotherapy for adults with overweight and obesity.
   Lancet. 2022;399:2100-2101.
   PubMed    
   
   
   
7. CHARALAMPAKIS V, Rajeev Y, Singhal R
   Adjustable intragastric balloon for obesity.
   Lancet. 2022;399:2099.
   PubMed    
   
   
   
8. BRUNALDI VO, Neto MG
   Adjustable intragastric balloon for obesity.
   Lancet. 2022;399:2099.
   PubMed    
   
   
   April 2022
9. CROSBIE EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al
   Endometrial cancer.
   Lancet. 2022;399:1412-1428.
   PubMed     Abstract available
   
   
   February 2022
10. TATUM M
    China's population peak.
    Lancet. 2022;399:509.
    PubMed    
    
    
    December 2021
11. SHI Q, Wang Y, Hao Q, Vandvik PO, et al
    Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2021 Dec 8. pii: S0140-6736(21)01640.
    PubMed     Abstract available
    
    
    November 2021
12. LAU DCW, Erichsen L, Francisco AM, Satylganova A, et al
    Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
    Lancet. 2021 Nov 16. pii: S0140-6736(21)01751.
    PubMed     Abstract available
    
    
    
13. ABU DAYYEH BK, Maselli DB, Rapaka B, Lavin T, et al
    Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02394.
    PubMed     Abstract available
    
    
    
14. SUDLOW A, le Roux CW
    Improving gastric balloons to treat obesity.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02505.
    PubMed    
    
    
    September 2021
15. LINGVAY I, Sumithran P, Cohen RV, le Roux CW, et al
    Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.
    Lancet. 2021 Sep 30. pii: S0140-6736(21)01919.
    PubMed     Abstract available
    
    
    August 2021
16. MEGHJI J, Mortimer K, Jayasooriya S, Marks GB, et al
    Lung health in LMICs: tackling challenges ahead - Authors' reply.
    Lancet. 2021;398:490.
    PubMed    
    
    
    
17. NEMERY B, Katoto PDMC, Develtere P
    Lung health in LMICs: tackling challenges ahead.
    Lancet. 2021;398:489-490.
    PubMed    
    
    
    
18. KHOO EM, Li D, Ungan M, Jordan R, et al
    Lung health in LMICs: tackling challenges ahead.
    Lancet. 2021;398:488-489.
    PubMed    
    
    
    July 2021
19. TEUFEL F, Seiglie JA, Geldsetzer P, Theilmann M, et al
    Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults.
    Lancet. 2021;398:238-248.
    PubMed     Abstract available
    
    
    
20. WANG L, Zhou B, Zhao Z, Yang L, et al
    Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18.
    Lancet. 2021;398:53-63.
    PubMed     Abstract available
    
    
    
21. FLEGAL KM
    BMI and obesity trends in Chinese national survey data.
    Lancet. 2021;398:5-7.
    PubMed    
    
    
    
22. SALAH RO, Ghandour R, Husseini A
    Prevalence of overweight, obesity, and associated factors among adolescents in the occupied Palestinian territory: a cross-sectional study.
    Lancet. 2021;398 Suppl 1:S46.
    PubMed     Abstract available
    
    
    June 2021
23. TREASURE J, Ambwani S
    Addressing weight stigma and anti-obesity rhetoric in policy changes to prevent eating disorders.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)01109.
    PubMed    
    
    
    May 2021
24. MINGRONE G, Bornstein SR
    Gain in survival after metabolic-bariatric surgery.
    Lancet. 2021;397:1785-1787.
    PubMed    
    
    
    
25. ENEBO LB, Berthelsen KK, Kankam M, Lund MT, et al
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.
    Lancet. 2021;397:1736-1748.
    PubMed     Abstract available
    
    
    
26. SYN NL, Cummings DE, Wang LZ, Lin DJ, et al
    Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.
    Lancet. 2021 May 6. pii: S0140-6736(21)00591.
    PubMed     Abstract available
    
    
    April 2021
27. BECERRIL S, Fruhbeck G
    Cagrilintide plus semaglutide for obesity management.
    Lancet. 2021 Apr 22. pii: S0140-6736(21)00944.
    PubMed    
    
    
    March 2021
28. LATINI R, Staszewsky L
    Semaglutide and effective weight control.
    Lancet. 2021;397:942-943.
    PubMed    
    
    
    
29. DAVIES M, Faerch L, Jeppesen OK, Pakseresht A, et al
    Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Lancet. 2021 Mar 2. pii: S0140-6736(21)00213.
    PubMed     Abstract available
    
    
    November 2020
30. CHAN JCN, Lim LL, Wareham NJ, Shaw JE, et al
    The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32374.
    PubMed    
    
    
    September 2020
31. HAWKES C, Ruel M, Wells JC, Popkin BM, et al
    The double burden of malnutrition-further perspective - Authors' reply.
    Lancet. 2020;396:815-816.
    PubMed    
    
    
    
32. STEWART CP, de Pee S, Maleta K, Michaelsen KF, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:814-815.
    PubMed    
    
    
    
33. OSENDARP SJM, Brown KH, Neufeld LM, Udomkesmalee E, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:813.
    PubMed    
    
    
    
34. HOSSAIN MS, Ferdous S, Raheem E, Siddiqee MH, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:813-814.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: